Cancer forces cells to grow and divide without the normal controls that keep tissues healthy. Instead of following the body’s signals to stop multiplying or to self-destruct when damaged, cancer cells ignore those signals, accumulate into masses called tumors, steal nutrients and blood supply from surrounding tissue, and can eventually spread to distant organs. What starts as a local problem can become a whole-body disease.
How Normal Cell Controls Break Down
Every cell in your body has built-in checkpoints that regulate when it divides, when it rests, and when it should die. One of the most important gatekeepers is a protein called p53, sometimes called the “guardian of the genome.” When DNA gets damaged, p53 normally halts cell division so the damage can be repaired, or triggers a self-destruct sequence (called apoptosis) if the damage is too severe to fix.
In most human cancers, the gene responsible for p53 is mutated. These mutations don’t just weaken p53’s function; they usually knock out both its ability to pause the cell cycle and its ability to trigger cell death. Without that checkpoint, damaged cells keep dividing. Each new division introduces more errors, and cells rapidly accumulate abnormal numbers of chromosomes. In lab studies, cells completely lacking p53 begin duplicating their entire DNA content when division is blocked, producing cells with double or quadruple the normal amount of genetic material. This snowballing instability is what transforms a single misbehaving cell into a mass of increasingly abnormal ones.
How Tumors Feed Themselves
Cancer cells are metabolically greedy. They consume glucose at a dramatically higher rate than normal cells, and they process it inefficiently, fermenting it into lactic acid even when oxygen is plentiful. This quirk, known as the Warburg effect, does something important: it generates the raw materials cancer cells need to keep building new cells at speed.
The lactic acid they produce isn’t just a waste product. It acidifies the surrounding tissue, which damages healthy cells nearby and creates conditions that help the tumor invade further. The heavy glucose consumption also starves immune cells in the area. Immune cells that have infiltrated the tumor need glucose to function, and when the tumor has already consumed most of the available supply, those immune cells can’t mount an effective attack.
Building a Blood Supply
A tumor can’t grow beyond a few millimeters without its own blood supply. To solve this, cancer cells hijack the body’s normal process for building new blood vessels. When tumor cells experience low oxygen, they activate a molecular switch that ramps up production of a signaling protein called VEGF. This protein latches onto the surface of nearby blood vessel cells and stimulates them to grow, multiply, and migrate toward the tumor, forming new capillaries that deliver oxygen and nutrients directly to it.
The process is self-reinforcing. As the tumor grows, more of its interior becomes oxygen-starved, which triggers even more VEGF production and more blood vessel growth. VEGF also increases the permeability of blood vessels, making it easier for cancer cells to slip into the bloodstream. This is one of the key links between a tumor’s growth and its ability to spread.
How Cancer Spreads to Other Organs
The spread of cancer to distant sites, called metastasis, is what makes the disease most dangerous. It follows a specific sequence. Cells in epithelial tissues (the type that lines organs and makes up most solid tumors) are normally locked tightly together by junctions that hold them in place. During metastasis, cancer cells dismantle those junctions, lose their polarity, and essentially transform into a more mobile cell type. They reshape their internal skeleton to form protrusions that let them crawl through tissue, and they produce enzymes that dissolve the structural matrix around them, carving a path toward blood or lymph vessels.
Once in the bloodstream, surviving cancer cells travel to distant organs. When they arrive at a new site, they can reverse the transformation, revert to a more stationary state, and begin growing a secondary tumor that resembles the original. This is why a breast cancer that spreads to the lungs is still breast cancer, not lung cancer. It carries the same genetic profile as the primary tumor.
Hiding From the Immune System
Your immune system is designed to recognize and destroy abnormal cells, and it eliminates early cancer cells routinely. Tumors that survive have typically developed ways to evade this surveillance. One of the most well-understood methods involves a surface protein that cancer cells display in large quantities. When this protein on a tumor cell connects with a receptor on a T cell (one of the immune system’s main attack cells), it sends a “stand down” signal. The T cell stops proliferating, stops activating, and eventually becomes exhausted, unable to carry out its normal killing function.
Cancer cells can also interfere with the immune system earlier in the process, during the stage when T cells are first being primed to recognize threats. By blocking the stimulatory signals that T cells need during this initial activation, tumors prevent the immune response from ramping up in the first place. The result is an immunosuppressive environment around the tumor where immune cells are present but functionally disabled. This understanding led to the development of immunotherapy drugs that block these “off switches” and restore the immune system’s ability to attack tumors.
Effects Beyond the Tumor
Cancer doesn’t only cause problems at the site where it grows. Tumors can release hormones, immune-triggering proteins, and other substances into the bloodstream that affect organs far from the tumor itself. These are called paraneoplastic syndromes, and they sometimes appear before the cancer is even diagnosed.
Some tumors produce hormones they aren’t supposed to make. For example, certain lung cancers secrete a hormone that causes the body to retain too much water, dangerously lowering sodium levels. Others release a substance that mimics parathyroid hormone, pulling calcium out of bones and raising blood calcium to levels that cause confusion, nausea, and kidney problems. Some tumors secrete substances that trigger excessive blood clotting, increasing the risk of dangerous clots in the legs or lungs. Others produce serotonin, causing flushing, diarrhea, and wheezing.
The immune system itself can become collateral damage. When the body mounts an immune response against tumor proteins, the antibodies it produces sometimes attack normal tissues that share similar molecular features, particularly nerve cells. This can lead to numbness, weakness, difficulty walking, or vision changes that seem completely unrelated to the cancer.
How Doctors Measure How Far It Has Gone
Cancer is staged based on three factors: the size of the primary tumor, whether it has reached nearby lymph nodes, and whether it has spread to distant parts of the body. These are labeled T, N, and M. A small tumor with no lymph node involvement and no distant spread might be classified as T1, N0, M0. A larger tumor that has reached several lymph nodes and spread to another organ might be T3, N2, M1.
These measurements are combined into an overall stage from 0 to IV. Stage 0 means abnormal cells are present but haven’t invaded surrounding tissue. Stages I through III indicate progressively larger tumors or more local spread. Stage IV means the cancer has metastasized to distant organs. The stage at diagnosis is one of the strongest predictors of outcome, because the biological processes described above (immune evasion, blood vessel growth, metabolic hijacking) have had more time to establish themselves in advanced disease.
Survival Varies Widely by Cancer Type
Not all cancers behave the same way, and survival rates reflect that. Based on cases diagnosed between 2014 and 2020, the five-year survival rate for prostate cancer is 97%, and for melanoma it’s 94%. Female breast cancer has a five-year survival rate of 91%, and colorectal cancer is 64%. Lung cancer, which is often diagnosed at a later stage, has a five-year survival rate of 27%.
These numbers represent averages across all stages. A lung cancer caught at stage I has a much better prognosis than one found at stage IV, which is why early detection matters so much. The biology of each cancer type also plays a role: some tumors grow slowly and rarely metastasize, while others are aggressive from the start, spreading before symptoms ever appear.